Gestational Diabetes: Screening, Treatment & Type 2 Risk

Table of contents

• Evidence summary
• What gestational diabetes is
• Symptoms and diagnosis
• The screening debate: NICE vs IADPSG and the GEMS trial
• Causes and risk factors
• Treatments that work
• Medicines: metformin, insulin and glibenclamide
• Supplements and lifestyle claims
• Risks of common treatments
• After birth: follow-up and type 2 diabetes risk
• Who to see
• Follow the money
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator, government body or trial funded wholly by a public research agency; 2 = academic or Cochrane team with no commercial funding for the work but some declared industry ties or donated product; 3 = organisation with substantial revenue from companies that sell treatments or devices for the condition; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D.

Sources cluster in three places: New Zealand and Australia, the US and the UK. Much of the trial and Cochrane evidence comes from one Auckland-based group. The strongest signal is convergence: NICE (cost-focused, UK), the New Zealand GEMS trial and the US NIH-funded Hillier trial all point the same way on thresholds, though they answer slightly different questions.

What gestational diabetes is

Gestational diabetes is high blood sugar that develops during pregnancy and usually disappears after birth. It can appear at any stage but is more common in the second or third trimester (NHS). It happens when the body cannot make enough extra insulin to meet the demands of pregnancy.

Some women found to have high sugar early in pregnancy actually had undiagnosed type 2 diabetes before. International guidance separates "overt diabetes in pregnancy" (for example fasting glucose of 7.0 mmol/L or more) from gestational diabetes (IADPSG 2010). The US ADA notes that gestational diabetes often represents previously undiagnosed prediabetes, type 2 diabetes or other forms (ADA 2026).

How common it is depends on who is tested and which cut-offs are used. The US Preventive Services Task Force puts US prevalence at 5.8% to 9.2% under traditional criteria, possibly higher with more inclusive ones (USPSTF 2021). Applying the IADPSG thresholds to the international HAPO cohort labelled 17.8% of pregnancies (IADPSG 2010).

Symptoms and diagnosis

Symptoms

Most women have no symptoms. Cases are usually found through screening. If sugar runs high, some notice more thirst, passing urine more often, dry mouth, tiredness, blurred vision, or genital itching or thrush. Many of these are common in pregnancy anyway (NHS).

How it is tested

The standard test is the oral glucose tolerance test (OGTT). You fast, give a blood sample, drink a measured glucose drink and give more blood samples. In the UK it is a 75 g, 2-hour test at 24 to 28 weeks for women with risk factors. Women with gestational diabetes in a previous pregnancy are offered early testing soon after booking, then again at 24 to 28 weeks if normal (NICE NG3, 1.2.5–1.2.7).

NICE advises against using fasting glucose alone, random glucose, HbA1c, the glucose challenge test or urine dipsticks to assess risk. Urine sugar of 2+ once, or 1+ twice or more, should prompt further testing (NICE NG3, 1.2.3–1.2.4).

In the US, the USPSTF recommends screening everyone at 24 weeks or later (grade B) but found too little evidence to judge screening before 24 weeks (USPSTF 2021). US practice uses either a one-step 75 g test or a two-step approach: a 50 g non-fasting challenge, then a 100 g 3-hour test if the first is raised (Hillier 2021).

Diagnostic thresholds compared

NICE's fasting cut-off is higher than IADPSG's but its 2-hour cut-off is lower. So the two systems do not simply rank as "strict" and "loose"; they pick up partly different women.

The screening debate: NICE vs IADPSG and the GEMS trial

Where the IADPSG thresholds came from

The HAPO study tested 25,505 pregnant women in nine countries and kept most results hidden from clinicians. Risk of a large baby and high cord-blood insulin rose smoothly with maternal glucose, with "no obvious thresholds" (HAPO 2008). Because there was no natural cut-off, the IADPSG panel chose the glucose levels at which the odds of these outcomes reached 1.75 times the odds at average glucose (IADPSG 2010). That was a consensus judgement, not a test of whether treating women above those lines helps. WHO adopted the same values in 2013 (WHO 2013).

Critics led by a New Zealand endocrinologist argued in the BMJ that the new criteria could triple prevalence while the effect on outcomes was unclear (Cundy et al. 2014).

The GEMS trial

GEMS put the question to a randomised test. In New Zealand, 4,061 women were tested at 24 to 32 weeks and randomly assigned to diagnosis by the lower IADPSG criteria or the higher New Zealand criteria (Crowther et al., NEJM 2022):

• Gestational diabetes was diagnosed in 15.3% with lower criteria vs 6.1% with higher criteria.
• Large-for-gestational-age babies: 8.8% vs 8.9% (adjusted RR 0.98, 95% CI 0.80 to 1.19). In plain terms, no difference.
• Induction of labour, use of health services, use of glucose-lowering medicines and newborn low blood sugar were all more common with the lower criteria.
• Among women whose results fell between the two sets of thresholds, those treated (195) had fewer large babies than those not treated (178). This was a secondary, non-randomised comparison, so it is a signal rather than proof.

A five-year follow-up of 869 mothers and 833 children found similar rates of maternal diabetes or prediabetes (20.5% vs 16.5%, p=0.10) and similar child BMI. The lower-criteria group had less hypertension and their children had less overweight and neurodevelopmental impairment, but these were secondary outcomes (GEMS follow-up 2025).

The US trial of one-step vs two-step testing

The ScreenR2GDM trial randomised 23,792 pregnancies in Kaiser Permanente. One-step testing (75 g, IADPSG-style) diagnosed 16.5% vs 8.5% with two-step testing (RR 1.94). Large babies (8.9% vs 9.2%), the perinatal composite (3.1% vs 3.0%), pre-eclampsia or gestational hypertension (13.6% vs 13.5%) and primary caesarean (24.0% vs 24.6%) did not differ. Only 66% of the one-step group actually had the assigned test (Hillier et al., NEJM 2021).

What about testing earlier in pregnancy?

The TOBOGM trial tested 802 higher-risk women before 20 weeks (mean 15.6 weeks) using WHO 2013 criteria. Immediate treatment modestly reduced a composite of adverse newborn outcomes (24.9% vs 30.5%; risk difference −5.6 points, 95% CI −10.1 to −1.2). It did not change pregnancy-related high blood pressure or newborn lean mass (Simmons et al., NEJM 2023). It was funded by Australia's NHMRC, the NSW Ministry of Health and Western Sydney University.

Our reading

Treating women with clearly raised glucose helps. Lowering the threshold to catch milder cases doubles the number of women labelled and treated, increases inductions and medicine use, and in two large trials did not improve the main outcomes for babies. That supports the UK's choice not to adopt the IADPSG thresholds, though NICE's own cut-offs were not tested in these trials either. The USPSTF did not pick a side.

Causes and risk factors

Pregnancy hormones make the body less sensitive to insulin. Most women make enough extra insulin to compensate; gestational diabetes develops when they cannot. Genes and extra weight also play a role (NIDDK).

NICE lists five risk factors to check at booking: BMI of 30 or more, a previous baby weighing 4.5 kg or more, previous gestational diabetes, a first-degree relative with diabetes, and an ethnicity with high diabetes prevalence (NICE NG3, 1.2.2). The NHS page also lists being over 40, south Asian, Black, African-Caribbean or Middle Eastern origin, and previous weight-loss surgery (NHS).

Being active before or early in pregnancy is linked with lower risk. An NIH-funded meta-analysis of observational studies found odds of gestational diabetes about 55% lower in the most vs least active women before pregnancy (OR 0.45, 95% CI 0.28 to 0.75) (Tobias 2011). Observational data cannot prove that exercise itself is the cause.

Risks if it is not treated

The NHS lists a larger-than-usual baby (raising the chance of induction or caesarean), too much amniotic fluid, premature birth, pre-eclampsia, low blood sugar or jaundice in the newborn and, rarely, stillbirth (NHS). NICE adds that if it is not detected and controlled there is a small increase in serious birth complications such as shoulder dystocia (NICE NG3, 1.2.1).

Treatments that work

NICE sets out a stepped approach (NICE NG3, 1.2.9–1.2.23 and 1.3.5):

• Review in a joint diabetes and antenatal clinic within 1 week of diagnosis.
• Teach home blood glucose monitoring. Targets (if achievable without problem hypos): fasting below 5.3 mmol/L and 1 hour after meals below 7.8 mmol/L (or 2 hours below 6.4 mmol/L).
• Refer everyone to a dietitian; advise regular exercise, such as walking for 30 minutes after a meal.
• If fasting glucose is below 7.0 mmol/L at diagnosis, try diet and exercise first. If targets are not met within 1 to 2 weeks, offer metformin. If metformin is unsuitable or declined, offer insulin. Add insulin if metformin plus diet does not meet targets.
• If fasting glucose is 7.0 mmol/L or more at diagnosis, offer insulin straight away, with or without metformin.
• Give birth no later than 40 weeks plus 6 days; offer induction or caesarean if not delivered by then (NG3 1.4.4).

The same Cochrane overview flagged a trade-off: lifestyle intervention probably increases induction of labour (RR 1.20, 0.99 to 1.46; moderate certainty) (Martis 2018). In ACHOIS, inductions also rose from 29% to 39%, but caesarean rates did not change (31% vs 32%), and women in the treatment group had less depression three months after birth (ACHOIS).

Medicines: metformin, insulin and glibenclamide

Metformin

In the MiG trial, 751 women with gestational diabetes were randomised to metformin (adding insulin if needed) or insulin. The newborn composite outcome was 32.0% vs 32.2% (RR 0.99, 95% CI 0.80 to 1.23). Almost half (46.3%) of the metformin group also needed insulin. Women strongly preferred metformin: 76.6% would choose it again vs 27.2% for insulin (Rowan et al., NEJM 2008).

A meta-analysis of 15 trials (2,509 women) found metformin led to less maternal weight gain (−1.14 kg) and a trend to less newborn low blood sugar than insulin, but slightly more preterm birth (RR 1.50, 1.04 to 2.16) (Balsells 2015). A Cochrane review found insulin linked to more hypertensive disorders of pregnancy than oral drugs (RR 1.89, 1.14 to 3.12; moderate certainty) (Brown 2017).

Metformin and the child: MiG TOFU and MiTy Kids

Metformin crosses the placenta, so long-term effects on children matter. In the MiG follow-up, children in the Adelaide subgroup did not differ at 7 years. In Auckland, metformin-exposed children were larger at 9 years (weight, waist and arm measures), but body fat percentage and metabolic blood tests were similar (Rowan et al. 2018). Only part of the original trial was followed up.

The MiTy trial is often cited in this debate but studied women with type 2 diabetes in pregnancy, not gestational diabetes. Adding metformin to insulin (n=502) did not change the main newborn composite (40% vs 40%) but lowered birth weight and roughly doubled small-for-gestational-age babies (13% vs 7%; RR 1.96, 1.10 to 3.64) (Feig et al. 2020). At 2 years, children's BMI and skinfolds were similar, although boys exposed to metformin had higher BMI between 6 and 24 months (MiTy Kids 2023). This is reassuring in the short term but cannot settle effects in later childhood.

The Irish EMERGE trial gave metformin or placebo straight after diagnosis (n=535 pregnancies). The main outcome, needing insulin or having high fasting glucose, was not significantly reduced (56.8% vs 63.7%; RR 0.89, 0.78 to 1.02). Babies were smaller, without differences in intensive care needs or low blood sugar (Dunne et al., JAMA 2023).

Insulin

Insulin does not cross the placenta in meaningful amounts and is the comparator in every trial. NICE uses it when metformin is unsuitable, declined or not enough, and from the start when fasting glucose is 7.0 mmol/L or more. The US ADA calls insulin the first-line agent in the US and says metformin and glyburide "should not be used as first-line agents" (ADA 2026, 15.21). The guidelines read the same trials differently: NICE leads with metformin, the ADA with insulin.

Glibenclamide (glyburide)

In the publicly funded French INDAO trial (914 women), the composite of large baby, newborn low blood sugar and jaundice was 27.6% with glibenclamide vs 23.4% with insulin. The trial "failed to show" glibenclamide was not worse, and the authors said the results did not justify it as first-line treatment (Sénat et al., JAMA 2018). The 2015 meta-analysis found glibenclamide was linked to heavier babies (+109 g), more macrosomia (RR 2.62) and more newborn hypoglycaemia (RR 2.04) than insulin, and concluded it should not be used if insulin or metformin is available (Balsells 2015). The current NICE NG3 recommendations page does not include glibenclamide in its treatment steps.

Supplements and lifestyle claims

Myo-inositol is the supplement with the most data, but six of its seven trials came from Italy. Two had women buy their own supplements, two did not state funding, and one received product free from Lo.Li. Pharma (Cochrane 2023 full text). For more detail see our myo-inositol review. Supplements should not replace monitoring or prescribed treatment. Discuss any supplement with your maternity team, because pregnancy safety data are thin for most of them.

Risks of common treatments

NICE advises stopping glucose-lowering treatment immediately after birth for women with gestational diabetes (NG3 1.6.3).

After birth: follow-up and type 2 diabetes risk

A meta-analysis of 20 studies covering 67,956 women with past gestational diabetes and 1.26 million controls found a nearly 10-fold higher risk of type 2 diabetes (RR 9.51, 95% CI 7.14 to 12.67) (Vounzoulaki et al., BMJ 2020). The ADA estimates the lifetime risk at 50–60% (ADA 2026).

What testing is recommended

NICE tells women with a postnatal fasting glucose below 6.0 mmol/L that they have a low probability of diabetes now but a moderate risk later, and women between 6.0 and 6.9 mmol/L that they are at high risk (NG3 1.6.12).

Can type 2 diabetes be prevented?

In the NIH-sponsored Diabetes Prevention Program, 350 women with past gestational diabetes and impaired glucose tolerance were followed. Both intensive lifestyle change and metformin cut diabetes incidence by about 50% compared with placebo (Ratner et al. 2008). This is a subgroup of a larger trial, but the direction is consistent.

Women who had gestational diabetes are also offered early testing in their next pregnancy (NG3 1.2.6). Breastfeeding is encouraged for all mothers, including those with diabetes (ADA 2026).

Who to see

• Midwife or GP: risk assessment at booking and arranging the glucose test.
• Joint diabetes and antenatal clinic: NICE says women should be seen within 1 week of diagnosis (NG3 1.2.9). The team usually includes an obstetrician, diabetes doctor, diabetes specialist midwife or nurse.
• Dietitian: NICE recommends referral for everyone with gestational diabetes (NG3 1.2.16).
• Maternity unit triage: for reduced baby movements or pre-eclampsia symptoms, at any hour.
• GP after birth: for the postnatal glucose test and yearly checks.

Some women who struggle with low blood sugar on insulin may be offered a continuous glucose monitor (NHS treatment page). NICE offers continuous monitors to all pregnant women with type 1 diabetes and says to consider real-time continuous monitoring for other pregnant women on insulin, which includes gestational diabetes, if they have problematic severe hypos or unstable glucose levels (NG3 1.3.17–1.3.19).

Follow the money

Who profits either way

Lower thresholds mean more women diagnosed, which means more glucose meters, test strips, clinic visits, dietitian time, and medicine use. GEMS showed medicine use and health-service use rose with lower criteria (GEMS). On the other side, health systems paying for care, such as the NHS, have a budget interest in fewer diagnoses. Neither interest makes either answer wrong; it is why we weight randomised trials over expert consensus.

The treatment industry

• Insulin: WHO reported in 2021 that three multinational companies control more than 90% of the insulin market (WHO). They are Novo Nordisk (Denmark), Eli Lilly (US) and Sanofi (France).
• Metformin and glibenclamide: old generics sold by many companies. In the trials we reviewed, Merck KGaA donated metformin and placebo to the Irish EMERGE trial (EMERGE).
• Glucose monitoring: Ascensia donated glucose strips to EMERGE (EMERGE). Abbott and Dexcom are among the device makers listed as ADA funders (ADA 2023).
• Supplements: Lo.Li. Pharma (Italy) supplied myo-inositol for one Cochrane-included trial (Cochrane 2023).

Who funds the guideline bodies

• NICE: an executive non-departmental public body sponsored by the UK Department of Health and Social Care (GOV.UK).
• USPSTF: an independent volunteer panel; Congress mandates AHRQ to support it, and members receive honoraria and travel costs (USPSTF 2021).
• American Diabetes Association: its own draft disclosure lists about $24.8 million from drug and device makers in 2023. The largest were Eli Lilly ($7.27 million), Abbott ($6.40 million), Novo Nordisk ($2.74 million), Genentech ($2.00 million), Xeris ($1.85 million) and Sanofi ($1.12 million) (ADA). The ADA also co-funded HAPO (IADPSG 2010). Its pregnancy guidance prefers insulin, the product of three of its larger funders, over cheap generics; it cites placental transfer and long-term safety as the reasons. Committee members' declarations are published separately.
• Cochrane: its policy bars commercial sponsors from funding reviews (Cochrane). The gestational diabetes reviews list UK Department of Health support and University of Auckland funding.

Who funded the key trials

• GEMS: project grant from the Health Research Council of New Zealand (University of Auckland), which receives funding appropriated by Parliament (HRC). The five-year follow-up authors declared no competing interests.
• ScreenR2GDM: US NIH (NICHD) grants (PubMed record).
• HAPO: NICHD and NIDDK grants plus the American Diabetes Association (IADPSG 2010).
• INDAO: French Ministry of Health; one author consulted for Ferring, unrelated (JAMA full text).
• MiTy / MiTy Kids: Canadian Institutes of Health Research; the lead author declared Novo Nordisk advisory board and Sanofi lecture honoraria, unrelated (MiTy Kids).
• TOBOGM: Australia's NHMRC, NSW Ministry of Health and Western Sydney University (PubMed record).
• Landon (US MFMU): NIH (NICHD); no conflicts reported (PubMed record).

Documented integrity events

We found no regulatory actions, recalls or legal cases specific to gestational diabetes diagnosis or treatment in the sources we reviewed. The main "integrity" issue is structural: diagnostic thresholds used worldwide were set by expert consensus rather than tested in trials, and when they were tested they did not deliver the expected benefit.

What this means: Unusually for a condition with a large drug and device market, the core evidence on gestational diabetes was paid for by governments. No key trial in this review was manufacturer-funded. Industry money sits mainly around the edges: donated drugs and strips, authors' speaker fees, and the funding of the American Diabetes Association, which co-funded the study behind the lower thresholds and whose guidance prefers insulin.

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Type 2 diabetes: prevention and management evidence
• Diabetes supplements: benefits, limits and safety
• Myo-inositol: PCOS, fertility and pregnancy trials
• Berberine: glucose evidence and safety
• Diabetes and heart disease
• Heart disease during pregnancy
• Perinatal and postpartum depression
• Sleep and pregnancy
• High blood pressure: prevention and management
• Peripartum cardiomyopathy

Frequently asked questions

Sources and funding notes

What we could not verify: the funding statements for the MiG trial (NEJM 2008) and the ACHOIS trial (NEJM 2005), because the journal pages blocked access and PubMed lists no grants; the full author disclosures of the GEMS NEJM paper beyond "Health Research Council of New Zealand and others"; the full IADPSG consensus panel membership and individual declarations (only the paper-level statement was reviewed); the declarations of interest of the NICE NG3 guideline committee; the funding of the 2014 BMJ critique by Cundy and colleagues; and whether earlier versions of NG3 included glibenclamide. We did not find a citable UK prevalence figure for gestational diabetes under NICE criteria and so did not give one.

1. NICE NG3. Diabetes in pregnancy: management from preconception to the postnatal period (2015, updated December 2020) — UK guideline; NICE funded via DHSC.
2. GOV.UK: National Institute for Health and Care Excellence — NICE status and sponsor.
3. US Preventive Services Task Force. Screening for gestational diabetes. JAMA 2021 — AHRQ-supported.
4. American Diabetes Association. 15. Management of diabetes in pregnancy: Standards of Care in Diabetes—2026 — professional charity; industry revenue disclosed.
5. American Diabetes Association. Revenue received from pharmaceutical/device makers, 2023 (unaudited draft) — ADA's own disclosure.
6. WHO. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy, 2013 — WHO.
7. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. NEJM 2008 — NICHD, NIDDK, ADA.
8. IADPSG Consensus Panel (Metzger BE et al.). Recommendations on diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010 — panel statement; one author declared device-research support.
9. Cundy T, Ackermann E, Ryan EA. Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. BMJ 2014 — analysis article; funding not verified.
10. Crowther CA et al. Lower versus higher glycemic criteria for diagnosis of gestational diabetes (GEMS). NEJM 2022 — Health Research Council of New Zealand and others.
11. Liu Q et al. Five-year follow-up of the GEMS trial. Diabetes Res Clin Pract 2025 — authors declared no competing interests.
12. University of Auckland news: GEMS results (August 2022) — confirms HRC project grant.
13. Health Research Council of New Zealand: about us — funded by parliamentary appropriation.
14. Hillier TA et al. A pragmatic, randomized clinical trial of gestational diabetes screening. NEJM 2021 — NICHD.
15. Simmons D et al. Treatment of gestational diabetes mellitus diagnosed early in pregnancy (TOBOGM). NEJM 2023 — NHMRC, NSW Ministry of Health, Western Sydney University.
16. Crowther CA et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes (ACHOIS). NEJM 2005 — funding not verified.
17. Landon MB et al. A multicenter, randomized trial of treatment for mild gestational diabetes. NEJM 2009 — NICHD; no conflicts reported.
18. Rowan JA et al. Metformin versus insulin for the treatment of gestational diabetes (MiG). NEJM 2008 — funding not verified.
19. Rowan JA et al. MiG TOFU: body composition and metabolic outcomes at 7–9 years. BMJ Open Diabetes Res Care 2018 — no competing interests declared.
20. Feig DS et al. Metformin in women with type 2 diabetes in pregnancy (MiTy). Lancet Diabetes Endocrinol 2020 — CIHR, Lunenfeld-Tanenbaum Research Institute, University of Toronto.
21. Feig DS et al. MiTy Kids: 24-month follow-up. Lancet Diabetes Endocrinol 2023 — CIHR; author honoraria from Novo Nordisk and Sanofi declared.
22. Dunne F et al. Early metformin in gestational diabetes (EMERGE). JAMA 2023 (full text) — Health Research Board of Ireland; drug and placebo from Merck KGaA; strips from Ascensia.
23. Sénat MV et al. Glyburide vs subcutaneous insulin (INDAO). JAMA 2018 (full text) — French Ministry of Health (PHRC 2011).
24. Balsells M et al. Glibenclamide, metformin, and insulin for gestational diabetes: systematic review and meta-analysis. BMJ 2015 — no external funding; travel grants from Lilly, Novo Nordisk, Sanofi declared.
25. Brown J et al. Insulin for the treatment of women with gestational diabetes. Cochrane 2017 — UK Department of Health; one author had Novo Nordisk and Sanofi honoraria.
26. Brown J et al. Oral anti-diabetic pharmacological therapies for gestational diabetes. Cochrane 2017 — University of Auckland grant; UK Department of Health.
27. Martis R et al. Treatments for women with gestational diabetes: an overview of Cochrane reviews. 2018 — Liggins Institute; authors of included reviews declared.
28. Motuhifonua SK et al. Myo-inositol for preventing gestational diabetes. Cochrane 2023 (full text) — University of Auckland; no author conflicts.
29. Okesene-Gafa KA et al. Probiotic treatment for women with gestational diabetes. Cochrane 2020 — Cochrane; in-kind probiotics for an author's earlier trial declared.
30. Vounzoulaki E et al. Progression to type 2 diabetes after gestational diabetes. BMJ 2020 — NIHR; two authors' industry ties declared.
31. Ratner RE et al. Prevention of diabetes in women with a history of gestational diabetes (Diabetes Prevention Program). J Clin Endocrinol Metab 2008 — NIH-sponsored.
32. Tobias DK et al. Physical activity before and during pregnancy and risk of gestational diabetes: meta-analysis. Diabetes Care 2011 — NIH intramural.
33. NHS: Gestational diabetes and treatment — UK public health service.
34. NHS: Pre-eclampsia; NHS: Your baby's movements; NHS: Low blood sugar — UK public health service.
35. NIDDK: Gestational diabetes — US NIH.
36. WHO news release: barriers to insulin availability (November 2021) — WHO.
37. Cochrane commercial sponsorship policy — Cochrane.

Educational research reviewed 7 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.